Cork, Ireland’s GlowDx was founded in 2015 to address the need for a fast, easy-to-use, accurate, and inexpensive diagnostic tool for dengue fever in the developing world.
With dengue fever, early detection is critical since patients reach the “danger zone” at five to six days post infection. Expensive equipment, turnaround times of several hours, and shorter shelf lives make early diagnosis particularly challenging in developing regions, according to information from the company's website.
GlowDx was one of eight finalists in the Health and Wearable Technologies category of the SXSW Accelerator pitch competition.
[Image courtesy of SWEETCRISIS/FREEDIGITALPHOTOS.NET]
|Get inspired to innovate during Massachusetts Medtech Week—register for BIOMEDevice Boston 2016, April 13-14.|